Prevention of Coronary Heart Disease: A Nonhormonal Approach

ABSTRACT

Coronary heart disease (CHD) is a common and serious health problem facing women as they move beyond the reproductive years. Until recently, many postmenopausal women and their physicians relied heavily on hormone therapy to prevent cardiovascular disease, neglecting the well-recognized nonhormonal aspects of cardiovascular health. Simple lifestyle changes-exercise, diet, weight control, and avoidance of tobacco-can significantly reduce the chance of heart disease and its major risk factors, which are essentially the same for men and women. As with men, obesity, hypertension, hyperlipidemia, and diabetes are the major risk factors for heart disease in women. This review discusses the epidemiologic studies linking these risk factors to CHD in women, the guidelines for screening, and a brief overview of treatment recommendations.

KEYWORDS

Coronary heart disease risk factors - obesity - metabolic syndrome in women - lifestyle - exercise

REFERENCES

• 1 Mosca L, Appel L J, Benjamin E J et al.. Evidence-based guidelines for cardiovascular disease prevention in women.  Circulation. 2004;  109 672-693
• 2 Blanchard D, Erblich J, Montgomery G H, Bovber D H. Read all about it: the over-representation of breast cancer in popular magazines.  Prev Med. 2002;  35 343-348
• 3 Anonymous. The heart truth, a national awareness campaign for women about heart disease.  Available at: http://www.nhlbi.nih.gov/health/hearttruth , Accessed May 18 2004; 
• 4 Mosca L, Ferris A, Fabunmi R, Robertson R M. Tracking women's awareness of heart disease: An American Heart Association National Study.  Circulation. 2004;  109 573-579
• 5 Stampfer M J, Hu F B, Manson J E, Rimm E B, Willett W C. Primary prevention of coronary heart disease in women through diet and lifestyle.  N Engl J Med. 2000;  343 16-22
• 6 Ewing G B, Selassie A W, Lopez C H, McCutcheon E P. Self-report of delivery of clinical preventive services by U.S. physicians: comparing specialty, gender, age, setting of practice, and area of practice.  Am J Prev Med. 1999;  17 62-72
• 7 Manson J E, Greenland P, LaCroix A Z et al.. Walking compared with vigorous exercise for the prevention of cardiovascular events in women.  N Engl J Med. 2002;  347 716-725
• 8 Hu F B, Stampfer M J, Solomon C et al.. Physical activity and risk for cardiovascular events in diabetic women [see comment].  Ann Intern Med. 2001;  134 96-105
• 9 Pate R R, Pratt M, Blair S N et al.. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine.  JAMA. 1995;  273 402-407
• 10 Ransdell L B, Wells C L. Physical activity in urban white, African-American, and Mexican-American women.  Med Sci Sports Exerc. 1998;  30 1608-1615
• 11 Mokdad A H, Ford E S, Bowman B A et al.. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.  JAMA. 2003;  289 76-79
• 12 Mokdad A H, Bowman B A, Ford E S, Vinicor F, Marks J S, Koplan J P. The continuing epidemics of obesity and diabetes in the united states.  JAMA. 2001;  286 1195-1200
• 13 Anonymous. Healthy weight, overweight, and obesity among persons 20 years of age and over, according to sex, age, race and Hispanic origin: United States. Available at: http://www.cdc.gov/nchs/data/hus/tables/2002/02hus070.pdf. Accessed April 21, 2004
• 14 Poehlman E T, Toth M J, Gardner A W. Changes in energy balance and body composition at menopause: a controlled longitudinal study.  Ann Intern Med. 1995;  123 673-675
• 15 Carr M C. The emergence of the metabolic syndrome with menopause.  J Clin Endocrinol Metab. 2003;  88 2404-2411
• 16 Alexander J K. Obesity and coronary heart disease.  Am J Med Sci. 2001;  321 215-224
• 17 Lean M E, Han T S, Seidell J C. Impairment of health and quality of life using new US federal guidelines for the identification of obesity.  Arch Intern Med. 1999;  159 837-843
• 18 Colditz G A, Hankinson S E, Hunter D J et al.. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.  , [see comments] N Engl J Med. 1995;  332 1589-1593
• 19 Garrison R J, Castelli W P. Weight and thirty-year mortality of men in the Framingham Study.  Ann Intern Med. 1985;  103(6) 1006-1009
• 20 Ridker P M, Manson J E, Buring J E, Shih J, Matias M, Hennekens C H. Homocysteine and risk of cardiovascular disease among postmenopausal women.  JAMA. 1999;  281 1817-1821
• 21 Sanchez-Margalet V, Valle M, Ruz F J, Gascon F, Mateo J, Goberna R. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects.  J Nutr Biochem. 2002;  13 75-79
• 22 Ridker P M, Stampfer M J, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.  JAMA. 2001;  285 2481-2485
• 23 Ridker P M, Buring J E, Shih J, Matias M, Hennekens C H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women [see comment].  Circulation. 1998;  98 731-733
• 24 Ridker P M, Buring J E, Cook N R, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.  Circulation. 2003;  107 391-397
• 25 Visser M, Bouter L M, McQuillan G M, Wener M H, Harris T B. Elevated C-reactive protein levels in overweight and obese adults.  JAMA. 1999;  282 2131-2135
• 26 Mavri A, Alessi M C, Bastelica D et al.. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.  Diabetologia. 2001;  44 2025-2031
• 27 Despres J P. Helath consequences of visceral obesity.  Ann Med. 2001;  33 534-541
• 28 Pouliot M-C, Despres J-P, Lemieux S et al.. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women.  Am J Cardiol. 1994;  73 460-468
• 29 Zhu S, Wang Z, Heshka S, Heo M, Faith M S, Heymsfield S B. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds.  Am J Clin Nutr. 2002;  76 743-749
• 30 Kanaya A M, Vittinghoff E, Shlipak M G et al.. Association of Total and Central Obesity with Mortality in Postmenopausal Women with Coronary Heart Disease.  Am J Epidemiol. 2003;  158 1161-1170
• 31 Zamboni M, Armellini F, Milani M P et al.. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships.  Int J Obes Relat Metabol Disord. 1992;  16 495-504
• 32 Toth M J, Tchernof A, Sites C K, Poehlman E T. Effect of menopausal status on body composition and abdominal fat distribution.  Int J Obes Relat Metaol Disord. 2000;  24 226-231
• 33 Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.  Br Med J (Clin Res Ed). 1984;  289 1257-1261
• 34 Williamson D F, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years.  Am J Epidemiol. 1995;  141 1128-1141
• 35 Wood P D, Stefanick M L, Williams P T, Haskell W L. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women.  N Engl J Med. 1991;  325 461-466
• 36 Fujioka S, Matsuzawa Y, Tokunaga K et al.. Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity.  Int J Obes. 1991;  15 853-859
• 37 MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues.  Eur Heart J. 1987;  8(suppl B) 57-70
• 38 Svendsen O L, Hassager C, Christiansen C, Nielsen J D, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.  Arterioscler Thromb Vasc Biol. 1996;  16 381-385
• 39 Tchernof A, Nolan A, Sites C K, Ades P A, Poehlman E T. Weight loss reduces C-reactive protein levels in obese postmenopausal women.  Circulation. 2002;  105 564-569
• 40 Tuomilehto J, Lindstrom J, Eriksson J G et al.. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 41 Knowler W C, Barrett-Connor E, Fowler S E et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 42 Jakicic J M, Marcus B H, Gallagher K I, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial.  JAMA. 2003;  290 1323-1330
• 43 Kraus W E, Houmard J A, Duscha B D et al.. Effects of the amount and intensity of exercise on plasma lipoproteins.  N Engl J Med. 2002;  347 1483-1492
• 44 Irwin M L, Yasui Y, Ulrich C M et al.. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial.  JAMA. 2003;  289 323-330
• 45 Anonymous. Screening for Obesity in Adults. December 2003 Available at: http://www.ahrq.gov/clinic/uspstf/uspsobes.htm. Accessed May 18, 2004
• 46 Kramer F M, Jeffery R W, Forster J L, Snell M K. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women.  Int J Obes. 1989;  13 123-136
• 47 Hong S, Friedman J, Alt S. Modifiable risk factors for the primary prevention of heart disease in women.  J Am Med Womens Assoc. 2003;  58 278-284
• 48 Bello N, Mosca L. Epidemiology of coronary heart disease in women.  Prog Cardiovasc Dis. 2004;  46 287-295
• 49 Pirkle J L, Flegal K M, Bernert J T, Brody D J, Etzel R A, Maurer K R. Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991.  JAMA. 1996;  275 1233-1240
• 50 Fiore M C, Bailey W C, Cohen S J. Treating Tobacco Use and Dependence. Quick Guide for Clinicians. Rockville, MD; Public Health Service 2000
• 51 Royce J M, Corbett K, Sorensen G, Ockene J. Gender, social pressure, and smoking cessations: the Community Intervention Trial for Smoking Cessation (COMMIT) at baseline.  Soc Sci Med. 1997;  44 359-370
• 52 Kottke T E, Stroebel R J, Hoffman R S. JNC 7-it's more than high blood pressure.  JAMA. 2003;  289 2573-2575
• 53 Chobanian A V, Bakris G L, Black H R et al.. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report.  JAMA. 2003;  289 2560-2571
• 54 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.  Circulation. 2002;  106 3143-3421
• 55 Hulley S, Grady D, Bush T et al.. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.  , [see comments] JAMA. 1998;  280 605-613
• 56 Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial.  JAMA. 2002;  288 321-333
• 57 Harris M I, Flegal K M, Cowie C C et al.. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.  , [see comment] Diabetes Care. 1998;  21 518-524
• 58 Brancati F L, Wang N Y, Mead L A, Liang K Y, Klag M J. Body weight patterns from 20 to 49 years of age and subsequent risk for diabetes mellitus: the Johns Hopkins Precursors Study.  Arch Intern Med. 1999;  159 957-963
• 59 Holbrook T L, Barrett-Connor E, Wingard D L. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community.  Int J Obes. 1989;  13 723-729
• 60 US Preventive Services Task Force . Screening for type 2 diabetes mellitus in adults: recommendations and rationale.  Ann Intern Med. 2003;  138 212-214
• 61 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 62 Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon M R, Heymsfield S B. The metabolic syndrome: prevalence and associated risk factor findings in the US Population from the Third National Health and Nutrition Examination Survey, 1988-1994.  Arch Intern Med. 2003;  163 427-436
• 63 Grundy S M, Brewer Jr H B, Cleeman J I, Smith Jr S C, Lenfant C. for the Conference Participants. Definition of Metabolic Syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition.  Circulation. 2004;  109 433-438
• 64 Isomaa B, Almgren P, Tuomi T et al.. Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes Care. 2001;  24 683-689
• 65 Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome.  Hum Reprod. 2002;  17 2495-2499
• 66 Hoeger K. Obesity and weight loss in polycystic ovary syndrome.  Obstet Gynecol Clin North Am. 2001;  28 85-97
• 67 Glueck C J, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.  Metabolism. 2003;  52 908-915
• 68 Talbott E O, Guzick D S, Sutton-Tyrrell K et al.. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.  Arterioscler Thromb Vasc Biol. 2000;  20 2414-2421
• 69 Andersen P, Seljeflot I, Abdelnoor M et al.. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.  Metabolism. 1995;  44 611-616
• 70 Randeva H S, Lewandowski K C, Drzewoski J et al.. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 4496-4501
• 71 Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial.  J Clin Endocrinol Metab. 2002;  87 569-574
• 72 Manson J E, Stampfer M J, Colditz G A et al.. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.  , [see comment] JAMA. 1991;  266 521-527